GRAIL GalleriThe Galleri multi-cancer early detection test screens for 50+ cancer types.
Category: Health, Medical and Biotech
Subcategory: Intelligent Diagnostics
From the winners: “The Galleri test detects a shared cancer signal across 50+ types of cancer with a single blood draw.”
“This groundbreaking technology finds more cancers at earlier stages — even before symptoms appear and when treatment is more likely to be successful. This could help prevent ~39% of cancer deaths that would otherwise occur in the next five years.”
“In the development of a molecular pregnancy test called non-invasive prenatal testing, abnormal signals were discovered in results from healthy pregnant women that indicated the possibility of cancer. Dr. Richard Klausner, a former NCI director, used sequencing technology to evolve the test to detect many early-stage cancers and maintain a low false-positive rate. A sub-study of Galleri showed that methylation, GRAIL’s approach, had the most promising combination of cancer detection and prediction of cancer signal origin when compared with others. Results formed the basis for how GRAIL refined the Galleri test to transform cancer care.”
“One in two to one in three of us will be diagnosed with cancer. Unfortunately, many cancers are detected too late, and cancers without screening recommendations represent ~70% of cancer deaths. We need to move from screening for individual cancers to screening individuals for cancer.”
“Multi-cancer early detection tests are designed to find more cancers earlier, prior to symptoms, through a simple blood draw. Galleri uses next-generation sequencing and machine-learning algorithms to analyze methylation patterns of cell-free DNA in the blood. That’s how Galleri can detect a signal across 50+ types of cancer and predict where cancer is in the body.”